Stoke Therapeutics Inc (STOK) P/E multiplikatori
Stoke Therapeutics sog'liqni saqlash gigantlari bilan hamkorlik orqali genetik terapiyalarni ishlab chiqmoqda, bu esa sinovlarni tezlashtiradi. Kompaniyaning P/E dinamikasi ushbu muvaffaqiyatlarning bozor qiymatini aks ettiradi, bunda -7.50 ushbu ko'rsatkichning joriy qiymatini ko'rsatadi. Ishlab chiqarish va IT infratuzilmasini autsorsing qilish orqali xarajatlarni optimallashtirish R&D samaradorligini qo'llab-quvvatlaydi, Dravet sindromi terapiyasi bo'yicha ijobiy ma'lumotlar esa qiymat o'sishining asosiy drayveri bo'lib xizmat qilmoqda.
Stoke (STOK) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- bozor narxi va tahlilchilarning maqsadli narxlari:
- bozor kapitallashuvi tafsilotlari:
- kompaniyaning balans qiymati tafsilotlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Jamlagan qarzning kapitalga nisbati Stoke Therapeutics|STOK - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Stoke Corp|STOK - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Stoke Therapeutics, Inc.|STOK - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli kredit va qarzlari Stoke Therapeutics|Tezkor likvidlik koeffitsiyenti stoketherapeutics.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
STOK - Kompaniyaning sof foydasi|Forvard foyda Stoke Therapeutics|STOK - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Stoke Therapeutics Inc|STOK - Narx-foyda va o‘sish multiplikatori|EV/EBITDA multiplikatori Stoke Therapeutics, Inc.|STOK - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi to'rtta chorak uchun bir aksiya uchun foyda Stoke Therapeutics|STOK - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi stoketherapeutics.com|STOK - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Stoke Therapeutics
Kompaniyaning jamlanma tahlili:STOK (stoketherapeutics.com)
P/E koeffitsiyenti biznesning bozor qiymatini uning yillik sof foydasiga nisbatan belgilaydi, bu esa investorga investitsiyalarning qoplanish muddatini baholash va qiymat tuzoqlaridan qochish imkonini beradi. Stoke Therapeutics (STOK) va uning RNA ga asoslangan umrbod terapiyalariga kelsak, joriy P/E baholash barqaror talab va kam uchraydigan kasalliklarning uzoq muddatli monetizatsiyasiga bo'lgan bozor kutganlarini aks ettiradi.
Raqobatdosh kompaniyalar tahlili
Kapitalizatsiyaning foydaga nisbati Tempus AI Inc TEM|Narxning foydaga nisbati Qiagen (QGEN)|P/E multiplikatori Ionis Pharmaceuticals, Inc. (IONS)|P/E multiplikatori RGEN (Repligen Corp.)|Avidity Corp (RNA) - Kapitalizatsiyaning foydaga nisbati|CRSP: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati WGS (genedx.com)|RARE (Ultragenyx) - Narx-foyda koeffitsiyenti|BEAM: Bozor narxining sof foydaga nisbati|SRPT (Sarepta Therapeutics Inc) - P/E multiplikatori|TWST: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori TXG|NTLA - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati BioLife Solutions BLFS|Kompaniya qiymatining sof foydaga nisbati WVE|Maze Tx - P/E multiplikatori|SION - P/E multiplikatori|Prime Medicine, Inc. (PRME) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati TSHA (tayshagtx.com)|QURE (uniQure) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati MeiraGTx Holdings MGTX|Narx-foyda koeffitsiyenti RGNX (Regenxbio)|P/E multiplikatori Solid Corp (SLDB)|Ocugen, Inc. - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati PACB (pacb.com)|Benitec Biopharma - P/E multiplikatori|Biznesning o‘zini qoplash muddati Design Therapeutics Inc DSGN|RCKT: P/E multiplikatori|Narx-foyda koeffitsiyenti 4D Molecular Corp|Narxning foydaga nisbati Lexeo Therapeutics Inc.|Korro Bio, Inc (KRRO) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Editas Medicine (EDIT)|Biznesning o‘zini qoplash muddati Silence Therapeutics PLC|ProQR Therapeutics - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati CDXS (Codexis Inc)|SGMO - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Nautilus Biotechnology|Metagenomi (MGX) - Narxning foydaga nisbati|precisionbiosciences.com (DTIL) - P/E multiplikatori|GBIO (Generation Bio Co) - P/E multiplikatori|Narx-foyda multiplikatori BOLD (Boundless Bio Inc)|Narxning foydaga nisbati Exicure, Inc. (XCUR)|imunon.com - Narx-foyda multiplikatori|P/E multiplikatori PHIO (Phio Pharmaceuticals Corp.)|P/E multiplikatori Mustang Bio Inc MBIO|RNAZ - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Bionano Genomics, Inc. BNGO|APDN (Applied DNA Sciences) - Narx-foyda koeffitsiyenti|BLUE: Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati ImmunoPrecise Antibodies Ltd|Kapitalizatsiyaning foydaga nisbati Omega Therapeutics Inc OMGA|Narxning foydaga nisbati Singular Genomics Systems Inc (OMIC)|P/E multiplikatori Regulus (RGLS)|P/E multiplikatori SYRS (Syros Pharmaceuticals)|telesisbio.com (TBIO) - Kapitalizatsiyaning foydaga nisbati|TCON: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati UBX (Unity Biotechnology Inc.)
